Merck, In A Statement, Says It Is Deeply Concerned By Advisory Committee on Immunization Practices Vote To Modify The Longstanding Hepatitis B Birth Dose Recommendation; Says The Decision Disregards Decades Of Safety And Effectiveness Data That Unequivocally Support Hepatitis B Birth Dose

Merck expresses strong concern over a CDC advisory panel's decision to revise the longstanding hepatitis B birth dose recommendation, citing decades of proven safety and effectiveness data.

Merck has issued a statement expressing deep concern over the Advisory Committee on Immunization Practices' (ACIP) decision to modify the longstanding recommendation for the hepatitis B birth dose. The company argues the change disregards extensive safety and efficacy data supporting the current practice. This reflects Merck's opposition to altering a long-standing public health recommendation.